Akero Therapeutics, Inc.
AKRO
$54.59
-$0.11-0.19%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.87% | 11.52% | 21.61% | 2.96% | 18.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.44% | 23.02% | 34.91% | 26.11% | 75.27% |
| Operating Income | -10.44% | -23.02% | -34.91% | -26.11% | -75.27% |
| Income Before Tax | -12.19% | -25.93% | -32.58% | -26.89% | -83.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.19% | -25.93% | -32.58% | -26.89% | -83.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.19% | -25.93% | -32.58% | -26.89% | -83.33% |
| EBIT | -10.44% | -23.02% | -34.91% | -26.11% | -75.27% |
| EBITDA | -10.44% | -23.01% | -34.90% | -26.08% | -75.29% |
| EPS Basic | 5.00% | -6.57% | 0.02% | -0.17% | -46.82% |
| Normalized Basic EPS | 6.82% | -6.56% | 0.04% | 4.02% | -46.83% |
| EPS Diluted | 5.00% | -6.57% | 0.02% | -0.17% | -46.82% |
| Normalized Diluted EPS | 6.82% | -6.56% | 0.04% | 4.02% | -46.83% |
| Average Basic Shares Outstanding | 18.10% | 18.16% | 32.62% | 26.66% | 24.87% |
| Average Diluted Shares Outstanding | 18.10% | 18.16% | 32.62% | 26.66% | 24.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |